Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 12, 2002 - Issue 9
Submit an article Journal homepage
92
Views
46
CrossRef citations to date
0
Altmetric
Miscellaneous

Human peptide transporters: therapeutic applications

Carsten Uhd Nielsen Department of Pharmaceutics, The Royal Danish School of Pharmacy, 2-Universitetsparken, DK-2100 Copenhagen, Denmark. [email protected]
,
Birger Brodin Department of Pharmaceutics, The Royal Danish School of Pharmacy, 2-Universitetsparken, DK-2100 Copenhagen, Denmark. [email protected]
,
Flemming Steen Jørgensen Department of Medicinal Chemistry, The Royal Danish School of Pharmacy, 2-Universitetsparken, DK-2100 Copenhagen, Denmark
,
Sven Frokjaer Department of Pharmaceutics, The Royal Danish School of Pharmacy, 2-Universitetsparken, DK-2100 Copenhagen, Denmark. [email protected]
&
Bente Steffansen Department of Pharmaceutics, The Royal Danish School of Pharmacy, 2-Universitetsparken, DK-2100 Copenhagen, Denmark. [email protected]
Pages 1329-1350 | Published online: 25 Feb 2005

Bibliography

  • ADIBI SA, MORSE EL: Intestinal transport of dipeptides in man; relative importance of hydrolysis and intact absorption. I Clin. Invest. (1971) 50:2266–2275.
  • NAKASHIMA E, TSUJI A, MIZUO H, YAMANA T: Kinetics and mechanism of in vitro uptake of amino-P-lactam antibiotics by rat small intestine and relation to the intact-peptide transport system. Biochem. Pharmacol. (1984) 33:3345–3352.
  • BRETSCHNEIDER B, BRANDSCH M, NEUBERT R Intestinal transport of P-lactam antibiotics: analysis of the affinity at the H+/ peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm. Rey. (1999) 16:55–61.
  • ••Investigates the affinities of a number of p- lactarn antibiotics and successfully correlates the values to oral bioavailabilities.
  • NICKLIN PL, IRWIN WJ, TIMMINS P,MORRISON RA: Uptake and transport of the ACE-inhibitor ceranopril (SQ 29852) by monolayers of human intestinal absorptive Caco-2 cells M vitro. Int. J. Pharm. (1996) 140:175–183.
  • THWAITES DT, CAVET M, HIRST BH, SIMMONS NL: Angiotensin-converting enzyme (ACE) inhibitor transport in human intestinal epithelial (Caco-2) cells. ELI-. Pharmacol. (1995) 114:981–986.
  • INUI K, TOMITA Y, KATSURA T, OKANO T, TAKANO M, HORI R: H± coupled active transport of bestatin via the dipeptide transport system in rabbit intestinal brush-border membranes J. Pharmacol. Exp. Ther. (1992) 260:482–486.
  • BOLL M, MARKOVICH D, WEBER WM, KORTE H, DANIEL H, MURER H: Expression cloning of a cDNA from rabbit small intestine related to proton-coupled transport of peptides, P-lactam antibiotics and ACE-inhibitors. Flingers Arch. (1994) 429:146–149.
  • DE VRUEH RL, SMITH PL, LEE CP: Transport of L-valine-acyclovir via the oligopeptide transporter in the human intestinal cell line, Caco-2. 1 Pharmacol. Exp. Ther. (1998) 286:1166–1170.
  • •The first study to show that the transport properties of L-valaciclovir are dependent on peptide transporter activity.
  • HAN H, VRUEH RLA, RHIE JK et al.: 5'-Amino acid esters of anti-viral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm. Res. (1998) 15:1154–1159.
  • PAULSEN IT, SKURRAY RA: The POT family of transport proteins. Trends Biochem. Sci. (1994) 19:404.
  • LIANG R, FEI YJ, PRASAD PD et al: Human intestinal HE/peptide cotransporter. Cloning, functional expression, and chromosomal localization. Bid. Chem. (1995) 270:6456–6463.
  • •Cloning of the human intestinal peptide transporter.
  • LIU W, LIANG R, RAMAMOORTHY S et al.: Molecular cloning of PEPT 2, a new member of the HE/peptide cotransporter family, from human kidney. Biochim. Biophys. Acta .(1995) 1235:461–466.
  • BOTKA CW, WITTIG TW, GRAUL RC et al.: Human Proton/oligopeptide transporter (POT) genes: identification of putative genes using bioinformatics. AAPS PharmSci. (2000) 2(2):E16.
  • DANTZIG AH, HOSKINS JA, TABAS LB et al.: Association of intestinal peptide transport with a protein related to the cadherin superfamily. Science (1994) 264:430–433.
  • ADIBI SA: Renal assimilation of oligopeptides: physiological mechanisms and metabolic importance. Am.' Physid. (1997) 272:E723–E736.
  • MATTHEWS DM: Intestinal absorption of peptides. Physid. Rev. (1975) 55:537–608.
  • ADIBI SA: The oligopeptide transporter (PepT-1) in human intestine: biology and function. Gastroenterology (1997) 113:332–340.
  • DANIEL H: Function and molecular structure of brush border membrane peptide/H+ symporters: j Mem& Biol. (1996) 154:197–203.
  • FEI YJ, GANAPATHY V, LEIBACH FH: Molecular and structural features of the proton-coupled oligopeptide transporter superfamily. Prog. Nucleic Add Res. (1998) 58:239–261.
  • MEREDITH D, BOYD CA: Structure and function of eukaryotic peptide transporters. Cell Mol Life ScL (2000) 57:754–778.
  • YANG CY, DANTZIG AH, PIDGEON C: Intestinal peptide transport systems and oral drug availability. Pharm. Res. (1999) 16:1331–1343.
  • BRODIN B, NIELSEN CU, STEFFANSEN B, FROKJAER S: Transport of peptidomimetic drugs by the intestinal di/tri-peptide transporter, PepTl. Pharmacol Toxicol (2002) 90:285–296.
  • GANAPATHY V, LEIBACH FH: Role of pH gradient and membrane potential in dipeptide transport in intestinal and renal brush-border membrane vesicles from the rabbit: Studies with L-carnosine and glycyl-L-proline. Biol. Chem. (1983) 258:14189–14192.
  • GANAPATHY V, LEIBACH FH: Is intestinal peptide transport energized by a proton gradient? Am. J. Physiol (1985) 249:G153–G160.
  • GANAPATHY V, MIYAMOTO Y, LEIBACH FH: Driving force for peptide transport in mammalian intestine and kidney. Beitr. Infusionther. Klin. Ernahr. (1987) 17:54–68.
  • CHEN XZ, ZHU T, SMITH DE, HEDI GER MA: Stoichiometry and kinetics of the high-affinity I-IF-coupled peptide transporter PepT2..1. Biol. Chem. (1999) 274:2773–2779.
  • MACKENZIE B, FEI YJ, GANAPATHY V, LEIBACH FH: The human intestinal Hioligopeptide cotransporter hPepT1 transports differently-charged dipeptides with identical electrogenic properties. Biochim. Biophys. Acta (1996) 1284:125–128.
  • WENZEL U, GEBERT I, WEINTRAUT H, WEBER WM, CLAUSS W, DANIEL H: Transport characteristics of differently charged cephalosporin antibiotics in oocytes expressing the cloned intestinal peptide transporter PepT1 and in human intestinal Caco-2 cells.' Pharmacol Exp. The]: (1996) 277:831–839.
  • THWAITES DT, FORD D, GLANVILLE M, SIMMONS NL: H(±)/ solute-induced intracellular acidification leads to selective activation of apical Na(±)/ H(±) exchange in human intestinal epithelial cells. Clin. Invest (1999) 104:629–635.
  • ALPERS DH: Uptake and fate of absorbedamino acids and peptides in the mammalian intestine. Fed. Proc. (1986) 45:2261–2267.
  • INUI K, YAMAMOTO M, SAITO H: Transepithelial transport of oral cephalosporins by monolayers of intestinal epithelial cell line caco-2: specific transport systems in apical and basolateral membranes. j. Pharmacol Exp. The]: (1992) 261:195–201.
  • IRIE M, TERADA T, SAWADA K, SAITO H, INUI KI: Recognition and transport characteristics of nonpeptidic compounds by basolateral peptide transporter in caco-2 cells. j Pharmacol Exp. The]: (2001) 298:711–717.
  • TERADA T, SAWADA K, SAITO H, HASHIMOTO Y, INUI K: Functional characteristics of basolateral peptide transporter in the human intestinal cell line Caco-2. Am. J. Physiol (1999) 276:G1435–G1441.
  • TERADA T, SAWADA K, ITO T, SAITO H, HASHIMOTO Y, INUI KI: Functional expression of novel peptide transporter in renal basolateral membranes. Am. j Physid Renal Physid. (2000) 279:F851–F857.
  • THWAITES DT, BROWN CDA, HIRST BH, SIMMONS NL: Transepithelial glycylsarcosine transport in intestinal caco-2 cells mediated by expression of H+-coupled carriers at both apical and basal membranes. j Biol. Chem. (1993) 268:7640–7642.
  • •Shows that the transepithelial transport of a dipeptide may be depedent on both apical and basolateral peptide transport activity.
  • SMITH DE, PAVLOVA A, BERGER UV et al.: Tubular localization and tissue distribution of peptide transporters in rat kidney. Pharm. Res. (1998) 15:1244–1249.
  • BOCKMAN DE, GANAPATHY V, OBLAK TG, LEIBACH FH: Localization of peptide transporter in nuclei and lysosomes of the pancreas. Int. j Pancreatol (1997) 22:221–225.
  • ZHOU X, THAMOTHARAN M, GANGOPADHYAY A, SERDIKOFF C, ADIBI SA: Characterization of an oligopeptide transporter in renal lysosomes. Biochim. Biophys. Acta (2000) 1466:372–378.
  • THAMOTHARAN M, LOMBARDO YB, BAWANI SZ, ADIBI SA: An active mechanism for completion of the final stage of protein degradation in the liver, lysosomal transport of dipeptides. 1 Biol. Chem. (1997) 272:11786–11790.
  • TERADA T, SAITO H, MUKAI M, INUI KI: Identification of the histidine residues involved in substrate recognition by a rat H±/peptide cotransporter, PepTl. FEBS Lett. (1996) 394:196–200.
  • FEI YJ, LIU W, PRASAD PD et al: Identification of the histidyl residue obligatory for the catalytic activity of the human HE/peptide cotransporters Peptl and PepT2. Biochemistry (1997) 36:452–460.
  • COVITZ KM, AMIDON GL, SADEE W: Human dipeptide transporter, hPepT1, stably transfected into Chinese hamster ovary cells. Pharm. Res. (1996) 13:1631–1634.
  • HAN HK, OH DM, AMIDON GL: Cellular uptake mechanism of amino acid ester prodrugs in Caco-2/hPepT1 cells overexpressing a human peptide transporter. Pharm. Res. (1998) 15:1382–1386.
  • HSU C, HILFINGER JM, WALTER E, MERKLE HP, ROESSLER BJ, AMIDON GL: Overexpression of human intestinal oligopeptide transporter in mammalian cells via adenoviral transduction. Pharm. Res. (1998) 15:1376–1381.
  • COVITZ KM, AMIDON GL, SADEE W: Membrane topology of the human dipeptide transporter, hPEPT1, determined by epitope insertions. Biochemistry (1998) 37:15214–15221.
  • AMASHEH S, WENZEL U, WAGENER M, WEBER WM, CLAUSS W, DANIEL H: Transport function of the renal peptide carrier rPepT2 expressed in Xenopus laevis oocytes. FASEB J. (1996) 10:465.
  • WENZEL U, THWAITES DT, DANIEL H: Stereoselective uptake of 13-lactam antibiotics by the intestinal peptide transporter. Br. J. Pharmacol (1995) 116:3021–3027.
  • DORING F, THEIS S, DANIEL H: Expression and functional characterization of the mammalian intestinal peptide transporter PepT1 in the methylotrophic yeast Fichte pastoris Biochem. Biophys. Res. Commun. (1997) 232:656–662.
  • DORING F, MICHEL T, ROSEL A, NICKOLAUS M, DANIEL H: Expression of the mammalian renal peptide transporter PEPT2 in the yeast Fichte pastoris and applications of the yeast system for functional analysis. MM. Membr: Biol. (1998) 15:79–88.
  • SAITO H, OKUDA M, TERADA T, SASAKI S, INUI K: Cloning and characterization of a rat H+/peptide cotransporter mediating absorption ofl3-lactam antibiotics in the intestine and kidney. Pharmacol Exp. Ther. (1995) 275:1631–1637.
  • FEI YJ, KANAI Y, NUSSBERGER S et al.: Expression cloning of a mammalian proton-coupled oligopeptide transporter. Nature (1994) 368:563–566.
  • ••Describes the first cloning of a di/tripeptide transporter.
  • FEI YJ, SUGAWARA M, LIU W et al.: cDNA structure, genomic organization, and promoter analysis of the mouse intestinal peptide transporter PEPT1. Biochimica et Biophysica Acta (2000) 1492:145–154.
  • WALKER D, THWAITES DT, SIMMONS NL, GILBERT HJ, HIRST BH: Substrate upregulation of the human small intestinal peptide transporter, hPepT1. j Physic] Loud. (1998) 507:697–706.
  • •An excellent study showing the up-regulation of peptide transporter activity in response to dipeptide substrates, and the cloning of hPepT1 from caco-2 cells.
  • http://www.pharmsci.org. Urtti A, Johns SJ, Sadee W: Genomic structure of proton-coupled oligopeptide transporter hPepT1 and pH-sensing regulatory splice variant. AAPS Pharmsci (2001).3: article 6
  • http://www.expasy.ch/prosite/
  • DORING F, DORN D, BACHFISCHER U, AMASHEH S, HERGET M, DANIEL H: Functional analysis of a chimeric mammalian peptide transporter derived from the intestinal and renal isoforms. I Physiol Loud. (1996) 497:773–779.
  • TERADA T, SAITO H, SAWADA K, HASHIMOTO K, INUI K: N-terminal halves of rat Hipeptide transporters are responsible for their substrate recognition. Pharm. Res. (2000) 17:15–20.
  • YEUNG AK, BASU SK, WU SK et al.: Molecular identification of a role for tyrosine 167 in the function of the human intestinal proton-coupled dipeptide transporter (hPepT1). Biochem. Biophys. Res. Commun. (1998) 250:103–107.
  • CHEN XZ, STEEL A, HEDIGER MA: Functional roles of histidine and tyrosine residues in the HE-peptide transporter PepT 1. Biochem. Biophys. Res. Commun. (2000) 272:726–730.
  • DORING F, MARTINI C, WALTER J, DANIEL H: Importance of a small N-terminal region in mammalian peptide transporters for substrate affinity and function. J. Membt: Biol. (2002) 186:55–62.
  • FRIEDMAN DI, AMIDON GL: Passive and carrier-mediated intestinal absorption components of two angiotensin converting enzyme (ACE) inhibitor prodrugs in rats: enalapril and fosinopril. Pharm. Res. (1989) 6:1043–1047.
  • FRIEDMAN DI, AMIDON GL: Intestinal absorption mechanism of dipeptide angiotensin converting enzyme inhibitors of the lysyl-proline type: lisinopril and SQ 29,852.1 Pharm. (1989) 78:995–998.
  • MOORE VA, IRWIN WJ, TIMMINS P et al.: A rapid screening system to determine drug affinities for the intestinal dipeptide transporter 2: affinities of ACE inhibitors. Int. J. Pharm.(2000) 210:29–44.
  • KRAMER W, GIRBIG F, GUTJAHR U et al.: Interaction of renin inhibitors with the intestinal uptake system for oligopeptides and 13-lactam antibiotics. Biochim. Biophys. Acta (1990) 1027:25–30.
  • WALTER E, KISSEL T, REERS M, DICKNEITE G, HOFFMANN D, STUBER W: Transepithelial transport properties of peptidomimetic thrombin inhibitors in monolayers of a human intestinal cell line (Caco-2) and their correlation to in vivo data. Pharm. Res. (1995) 12:360–365.
  • BALIMANE PV, TAMAI I, GUO A et al.: Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir. Biochem. Biophys. Res. Commun. (1998) 250:246–251.
  • HUM, SUBRAMANIAN P, MOSBERG HI, AMIDON GL: Use of the peptide carrier system to improve the intestinal absorption of L-a-methyldopa: carrier kinetics, intestinal permeabilities, and in vitro hydrolysis of dipeptidyl derivatives of L-a-methyldopa. Pharm. Res. (1989) 6:66–70.
  • SUGAWARA M, HUANG W, FEI YJ, LEIBACH FH, GANAPATHY V, GANAPATHY ME: Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. Pharm. Sci.(2000) 89:781–789.
  • WANG HP, LU HH, LEE JS et al.: Intestinal absorption studies on peptide mimetic a-methyldopa prodrugs. j. Pharm. Pharmacol (1996) 48:270–276.
  • EZRA A, HOFFMAN A, BREUER E et al.: A peptide prodrug approach for improving bisphosphonate oral absorption. J. Med. Chem. (2000) 43:3641–3652.
  • WEISS WJ, MIKELS SM, PETERSEN PJ et al.: In vivo activities of peptidic prodrugs of novel aminomethyl tetrahydrofuranyl-1 P-methylcarbapenems. Antimicrob. Agents Chemother: (1999) 43:460–464.
  • LIU.K., KATO Y, KAKU T et al: Hydroxyprolylserine derivatives JBP923 and JNP485 exhibit the antihepatitis activities after gastrointestinal absorption in rats. I Pharmacol Exp. Ther. (2000) 294:510–515.
  • SURENDRAN N, COVITZ KM, HAN H et al.: Evidence for overlapping substrate specificity between large neutral amino acid (LNAA) and dipeptide (hPEPT1) transporters for PD 158473, an NMDA antagonist. Pharm. Res. (1999) 16:391–395.
  • MORRISON RA, CHONG S, MARINO AM et al.: Suitability of enalapril as a probe of the dipeptide transporter system: in vitro and in vivo studies. Pharm. Res. (1996) 13:1078–1082.
  • SWAAN PW, STEHOUWER MC, TUKKER JJ: Molecular mechanism for the relative binding affinity to the intestinal peptide carrier. Comparison of three ACE-inhibitors: enalapril, enalaprilat, and lisinopril. Biochim. Biophys. Acta (1995) 1236:31–38.
  • BOLL M, HERGET M, WAGENER M et al. Expression cloning and functional characterization of the kidney cortex high-affinity proton-coupled peptide transporter. Proc. Natl Acad. ScL USA (1996) 93:284–289.
  • •Describes the expression cloning of PepT2.
  • DIECK ST, HEUER H, EHRCHEN J, OTTO C, BAUER K: The peptide transporter PepT2 is expressed in rat brain and mediates the accumulation of the fluorescent dipeptide derivative I3-Ala-Lys-Nepsilon-AMCA in astrocytes. Clia (1999) 25:10–20.
  • •Describes the expression and transport activity of PepT2 in rat brain.
  • SAITO H, TERADA T, OKUDA M, SASAKI S, INUI K: Molecular cloning and tissue distribution of rat peptide transporter PEPT2. Biochirm Biophys. Acta (1996) 1280:173–177.
  • WANG H, FEI YJ, GANAPATHY V, LEIBACH FH: Electrophysiological characteristics of the proton-coupled peptide transporter PEPT2 cloned from rat brain. Am. J. Physiol (1998) 275:C967–C975.
  • BERGER UV, HEDIGER MA: Distribution of peptide transporter PEPT2 mRNA in the rat nervous system. Anat. Embryo]. (Ben) (1999) 199:439–449.
  • GRONEBERG DA, NICKOLAUS M, SPRINGER J, DORING F, DANIEL H, FISCHER A: Localization of the peptide transporter PEPT2 in the lung: implications for pulmonary oligopeptide uptake. Am. J. Pathol (2001) 158:707–714.
  • •A study of the expression and transport activity of PepT2 in human lung tissue.
  • GRONEBERG DA, EYNOTT PR, DORING F et al: Distribution and function of the peptide transporter PEPT2 in normal and cystic fibrosis human lung. Thorax (2002) 57:55–60.
  • GRONEBERG DA, DORING F, THEIS S, NICKOLAUS M, FISCHER A, DANIEL H: Peptide transport in the mammary gland: expression and distribution of PEPT2 mRNA and protein. Am. J. Physiol Endocrinol Metab (2002) 282:E1172–E1179.
  • DRINGEN R, HAMPRECHT B, BROER S. The peptide transporter PepT2 mediates the uptake of the glutathione precursor CysGly in astroglia-rich primary cultures. Neurochem. (1998) 71:388–393.
  • SHU C, SHEN H, TEUSCHER NS, LORENZI PJ, KEEP RF, SMITH DE: Role of PepT2 in peptide/mimetic trafficking at the blood-cerebrospinal fluid barrier: studies in rat choroid plexus epithelial cells in primary culture. Pharmacol Exp. The]: (2002) 301:820–829.
  • BRANDSCH M, BRANDSCH C, PRASAD PD, GANAPATHY V, HOPFER U, LEIBACH FH: Identification of a renal cell line that constitutively expresses the kidney-specific high-affinity HE/peptide cotransporter. FASEB J. (1995) 9:1489–1496.
  • •Introduction of the SKPT cell line as a powerful in vitro system to study PepT2.
  • SHU C, SHEN H, HOPFER U, SMITH DE. Mechanism of intestinal absorption and renal reabsorption of an orally active ace inhibitor: uptake and transport of fosinopril in cell cultures. Drug Metab Dispos. (2001) 29:1307–1315.
  • TERADA T, SAITO H, MUKAI M, INUI K: Recognition of I3-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells. Am. Physiol (1997) 273:F706–F711.
  • WENZEL U, DIEHL D, HERGET M, DANIEL H: Endogenous expression of the renal high-affinity H+-peptide cotransporter in LLC-PK1 cells. Am. J. Physio1(1998) 275:C1573–C1579.
  • RUBIO-ALIAGA I, BOLL M, DANIEL H: Cloning and characterization of the gene encoding the mouse peptide transporter PEPT2. Biochem. Biophys. Res. Commun. (2000) 276:734–741.
  • RAMAMOORTHY S, LIU W, MA YY, YANG-FENG TL, GANAPATHY V, LEIBACH FH: Proton/peptide cotransporter (PEPT 2) from human kidney: functional characterization and chromosomal localization. Biochim. Biophys. Acta (1995) 1240:1–4.
  • TERADA T, SAWADA K, IRIE M, SAITO H, HASHIMOTO Y, INUI K: Structural requirements for determining the substrate affinity of peptide transporters PEPT1 and PEPT2. Pflugers Arch. (2000) 440:679–684.
  • DANIEL H, ADIBI SA: Transport of 13-lactam antibiotics in kidney brush border membrane. Determinants of their affinity for the oligopeptide/H+ symporter. j Invest (1993) 92:2215–2223.
  • GANAPATHY ME, BRANDSCH M, PRASAD PD, GANAPATHY V, LEIBACH FH: Differential recognition of 13 -lactam antibiotics by intestinal and renal peptide transporters, PEPT 1 and PEPT 2. J. Biol. Chem. (1995) 270:25672–25677.
  • INUI K, TERADA T, MASUDA S, SAIT H: Physiological and pharmacological implications of peptide transporters, PEPT1 and PEPT2. Nephrol. Dial. Transplant. (2000) 15 (Suppl. 6):11–13.
  • ZHU T, CHEN X-Z, STEEL A, HEDIGER MA, SMITH DE: Differential recognitionof ACE inhibitors in Xenopus laevis oocytes expressing rat PepT1 and PepT2. Pharm. Res. (2000) 17:526–532.
  • DORING F, WALTER J, WILL Jet al.: 8-aminolevulinic acid transport by intestinal and renal peptide transporters and its physiological and clinical implications. J. Clin. Invest. (1998) 101:2761–2767.
  • TAKAGI H, SHIOMI H, UEDA H, AMANO H: Morphine-like analgesia by a new dipeptide, L-tyrosyl-L-arginine (Kyotorphin) and its analogue. Ear: J. Pharmacol (1979) 55:109–111.
  • FUJITA T, KISHIDA T, OKADA N, GANAPATHY V, LEIBACH FH, YAMAMOTO A: Interaction of kyotorphin and brain peptide transporter in synaptosomes prepared from rat cerebellum: implication of high affinity type HE/peptide transporter PEPT2 mediated transport system. Neurosci. Lett. (1999) 271:117–120.
  • •Demonstrates uptake of the endogenous brain peptide kyotorphin from rat brain synaptasomes, and argues that this could be due to PepT2 activity.
  • TAMURA K, BHATNAGER P, TAKATA JS, LEE CP, SMITH PL, BORCHARDT RT: Metabolism, uptake, and transepithelial transport of the stereoisomers of Val-Val in the human intestinal cell line, Caco-2. Pharm. Res. (1996) 13:1213–1218.
  • TAMURA K, LEE CP, SMITH PL, BORCHARDT RT: Metabolism, uptake, and transepithelial transport of the stereoisomers of Val-Val-Val in the human intestinal cell line, Caco-2. Pharm. Res. (1996) 13:1663–1667.
  • MATHEWS DM, ADIBI SA: Peptide absorption. Gastroenterology (1976) 71:151–161.
  • TEMPLE CS, STEWART AK, MEREDITH D et al.: Peptide mimics as substrates for the intestinal peptide transporter. Biol. Chem. (1998) 273:20–22.
  • DORING F, WILL J, AMASHEH S, CLAUSS W, AHLBRECHT H, DANIEL H: Minimal molecular determinants of substrates for recognition by the intestinal peptide transporter. I Biol. Chem. (1998) 273:23211–23218.
  • BRANDSCH M, THUNECKE F, KULLERTZ G, SCHUTKOWSKI M, FISCHER G, NEUBERT K: Evidence for the absolute conformational specificity of the intestinal H±/peptide symporter, PEPT1. J. Biol. Chem. (1998) 273:3861–3864.
  • BRANDSCH M, KNOTTER I, THUNECKE F et al.: Decisive structural determinants for the interaction of proline derivatives with the intestinal HE/peptide symporter. Ear: Biochem. (1999) 266:502–508.
  • ADDISON JM, BURSTON D, MATTHEWS DM: Evidence for active transport of the dipeptide glycylsarcosine by hamster jejunum M vitro Clin. Sri. (1972) 43:907–911.
  • MATTHEWS DM: Mechanisms of peptide transport: Beitr. Infusionther. Kiln. Erna& (1987) 17:6–53.
  • HUM, AMIDON GL: Passive and carrier-mediated intestinal absorption components of captopril. ./. Pharm. Sci. (1988) 77:1007–1011.
  • BAI PF, SUBRAMANIAN P, MOSBERG HI, AMIDON GL: Structural requirements for the intestinal mucosal-cell peptide transporter: the need for N-terminal a-amino group. Pharm. Res. (1991) 8:593–599.
  • WALTER E, KISSEL T, AMIDON GL: The intestinal peptide carrier: a potential transport system for small peptide derived drugs. Adv. Drug Deily. Rev. (1996) 20:33–58.
  • FUJITA T, MORISHITA Y, ITO H, KURIBAYASHI D, YAMAMOTO A, MURANISHI S: Enhancement of the small intestinal uptake of phenylalanyl-glycine via a H±/oligopeptide transport system by chemical modification with fatty acids. Life Sciences (1997) 61:2455–2465.
  • MEREDITH D, TEMPLE CS, GUHA N, et al:Modified amino acids and peptides as substrates for the intestinal peptide transporter PepTl. Eur. I Biochem. (2000) 267:3723–3728.
  • BORNER V, FEI YJ, HARTRODT B et al. Transport of amino acid aryl amides by the intestinal H±/peptide cotransport system, PEPT1. Eur.j Biochem. (1998) 255:698–702.
  • SWAAN PW, TUKKER JJ: Molecular determinants of recognition for the intestinal peptide carrier. Pharm. Sci. (1997) 86:596–602.
  • SWAAN PW, KOOPS BC, MORET EE, TUKKERJJ: Mapping the binding site of the small intestinal peptide carrier (PepT1) using comparative molecular field analysis. Receptors Channels (1998) 6:189–200.
  • BAILEY PD, BOYD CAR, BRONK JR et al.: How to make drugs orally active: a substrate template for peptide transporter PepT 1. Angew. Chem. Int. Ed (2000) 39:505–508.
  • NIELSEN CU, ANDERSEN R, BRODIN B, FROKJAER S, TAUB ME, STEFFANSEN B: Dipeptide model prodrugs for the intestinal oligopeptide transporter. Affinity to and transport via hPepT1 in the human intestinal Caco-2 cell line. I Controlled Release (2001) 76:129–138.
  • KNOTTER I, THEIS S, HARTRODT B, et al.: A novel inhibitor of the mammalian peptide transporter PepTl. Biochemistry (2001) 40:4454–4458.
  • DANIEL H, MORSE EL, ADIBI SA: Determinants of substrate affinity for the oligopeptide/H+ symporter in the renal brush border membrane. I Biol. Chem. (1992) 267:9565–9573.
  • THEIS S, HARTRODT B, KOTTRA G, NEUBERT K, DANIEL H: Defining minimal structural features in substrates of the H(F)/peptide cotransporter PEPT2 using novel amino acid and dipeptide derivatives. Mol Pharmacol (2002) 61:214–221.
  • LIN CJ, AKARAWUT W, SMITH DE: Competetive inhibition of glycylsarcosine transport by enalapril in rabbit renal brush border membrane vesicles: interaction of ACE inhibitors with high-affinity HI peptide transporter. Pharm. Res. (1999) 16:609–615.
  • THEIS S, KNUTTER I, HARTRODT B et al.: Synthesis and characterization of high-affinity inhibitors of the HE/peptide transporter PEPT2. I Biol. Chem. (2002) 277:7287–7292.
  • DANIEL H, MORSE EL, ADIBI SA: The high and low affinity transport systems for dipeptides in kidney brush border membrane respond differently to alterations in pH gradient and membrane potential. J. Biol. Chem (1991) 266:19917–19924.
  • PIES M, WENZEL U, DANIEL H: Transport of cefadroxil in rat kidney brush-border membranes is mediated by two electrogenic H+-coupled systems. Pharmacol Exp. Ther. (1994) 271:1327–1333.
  • DANTZIG AH: Oral absorption of 13-lactams by intestinal peptide transport proteins. Adv. Drug Deliver. Rev (1997) 23:63–76.
  • •A comprehensive review discussing peptide transporter mediated uptake of p-lactarns.
  • GOCHOCO CH, RYAN FM, MILLER J, SMITH PL, HIDALGO IJ: Uptake and transepithelial transport of the orally absorbed cephalosporin cephalexin, in the human intestinal cell line, caco-2. hat. Pharm. (1994) 104:187–202.
  • HUM, CHEN J, ZHU Y, DANTZIG AH, STRATFORD REJ, KUHFELD MT: Mechanism and kinetics of transcellular transport of a new I3-lactam antibiotic loracarbef across an intestinal epithelial membrane model system (Caco-2). Pharm. Res. (1994) 11:1405–1413.
  • KIM JS, OBERLE RL, KRUMMEL DA, DRESSMAN JB, FLEISHER D: Absorption of ACE inhibitors from small intestine and colon. I Pharm. Sci. (1994) 83:1350–1356.
  • AMIDON GL, LENNERNAS H, SHAH VP, CRISON JR: A theoretical basis for a biopharmaceutical classification: the correlation of M vitro drug prodruct dissolution and in vivo bioavalability. Pharm. Res. (1995) 12:413–420.
  • ALBERT A: Chemical aspects of selective toxicity. Nature (1958) 182:421–423.
  • FRIEDRICHSEN GM, JAKOBSEN P, TAUB M, BEGTRUP M: Application of enzymatically stable dipeptides for enhancement of intestinal permeability. Synthesis and M vitro evaluation of dipeptide-coupled compounds. Bioorg. Med. Chem. (2001) 9:2625–2632.
  • TAUB ME, LARSEN BD, STEFFANSEN B, FROKJAER S: 13-carboxylic acid esterified D-Asp-Ala retains a high affinity for the oligopeptide transporter in Caco-2 monolayers. hat. Flamm. (1997) 146:205–212.
  • TAUB ME, MOSS BA, STEFFANSEN B, FROKJAER S: Ofigopeptide transporter mediated uptake and transport of D-Asp(OBzfi-Ala, D-Glu(OBz1)-Ala, and D-Ser(Bzfi-Ala in filter-grown Caco-2 monolayers. Intl Pharm. (1998) 174:223–232.
  • STEFFANSEN B, LEPIST El, TAUB ME, LARSEN BD, FROKJAER S, LENNERNAS H: Stability, metabolism and transport of D-Asp(OBz1)-Ala - a model prodrug with affinity for the oligopeptide transporter. Eur. I Amin. Sci. (1999) 8:67–73.
  • LEPIST El, KUSK T, LARSEN DH et al.: Stability and in vitro metabolism of dipeptide model prodrugs with affinity for the oligopeptide transporter. Eur. I Amin. Sci. (2000) 11:43–50.
  • NIELSEN CU, ANDERSEN R, BRODIN B, FROKJAER S, STEFFANSEN B: Model prodrugs for the intestinal oligopeptide transporter: model drug release in aqueous solution and in various biological media.' Control. Release (2001) 73:21–30.
  • THOMSEN AE, FRIEDRICHSEN GM, SORENSEN AH et al.: Prodrugs of purine and pyrimidine analogues for the intestinal di/ tri-peptide transporter hPepTl: Drug release in aqueous media and in vitro metabolism.' Control Release (2002) (In Press).
  • BAT JP: pG1u-L-Dopa-Pro: a tripeptide prodrug targeting the intestinal peptide transporter for absorption and tissue enzymes for conversion. Flamm. Res. (1995) 12:1101–1104.
  • TAMAI I, NAKANISHIT, NAKAHARA H et al.: Improvement of L-dopa absorption by dipeptidyl derivation, utilizing peptide transporter PepTl. Flamm. Sci. (1998) 87:1542–1546.
  • TANAKA M, HOHMURA M, NISHI T, SATO K, HAYAKAWA I: Antimicrobial activity of DU-6681a, a parent compound of novel oral carbapenem DZ-2640. Antimicrob. Agents Chen-tot/7er. (1997) 41:1260–1268.
  • DE MIRANDA P, BURNETTE TC: Metabolic fate and pharmacokinetics of the acyclovir prodrug valaciclovir in cynomolgus monkeys. Drug Metab. Dispos. (1994) 22:55–59.
  • JUNG D, DORR A: Single-dose pharmacokinetics of valganciclovir in HIV-and CMV- seropositive subjects. Clin. Phannacol. (1999) 39:800–804.
  • WELLER S, BLUM MR, DOUCETTE M et al.: Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin. Pharinacol. Ther. (1993) 54:595–605.
  • JAKOBSEN MA, DE MIRANDA P, CEDERBERG DM et al.: Human pharmacokinetics and tolerance of oral ganciclovir. Antimicrob. Agents Cheinother. (1987) 31:1251–1254.
  • SOUL-LAWTON J, SEABER E, ON N, WOOTTON R, ROLAN P, POSNER J: Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob. Agents Cheinother. (1995) 39:2759–2764.
  • GANAPATHY ME, HUANG W, WANG H, GANAPATHY V, LEIBACH FH: Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochein. Biophys. Res. Commun. (1998) 246:470–475.
  • FORBES B, WILSON CG, GUMBLETON M: Temporal dependence of ectopeptidase expression in alveolar epithelial cell culture: implications for study of peptide absorption. Int. j Pharm.(1999) 180:225–234.
  • NOVOTNY A, XIANG J, STUMMER W, TEUSCHER NS, SMITH DE, KEEP RF: Mechanisms of 5-aminolevulinic acid uptake at the choroid plexus. JNeurochem. (2000) 75:321–328.
  • TEUSCHER NS, NOVOTNY A, KEEP RF, SMITH DE: Functional evidence for presence of PepT2 in rat choroid plexus: Studies with glycylsarcosine. j Pharmacol. Exp. Ther. (2000) 294:494–499.
  • TEUSCHER NS, KEEP RF, SMITH DE: PEPT2-mediated uptake of neuropeptides in rat choroid plexus. Pharm. Res. (2001) 18:807–813.
  • NEALE JH, BZDEGA T, WROBLEWSKA B: N-Acetylaspartylglutamate: the most abundant peptide neurotransmitter in the mammalian central nervous system. .1 Neurochem. (2000) 75:443–452.
  • SHAVE E, PUSS L, LAWRANCE ML, FITZGIBBON T, STASTNY F, BALCARVJ: Regional distribution and pharmacological characteristics of MN- acetyl-aspartyl-glutamate (NAAG) binding sites in rat brain. Neurochem. hat. (2001) 38:53–62.
  • BASU SK, HAWORTH IS, BOLGER MB, LEE VH: Proton-driven dipeptide uptake in primary cultured rabbit conjunctival epithelial cells. Invest. Ophthalmol. Vis. Sci. (1998) 39:2365–2373.
  • YANG JJ, UEDA H, KIM K, LEE VH: Meeting future challenges in topical ocular drug delivery: development of an air-interfaced primary culture of rabbit conjunctival epithelial cells on a permeable support for drug transport studies. J. Control Release (2001) 65:1–11.
  • TAK RV, PAL D, GAO H, DEY S, MITRA AK: Transport of acyclovir ester prodrugs through rabbit cornea and SIRC-rabbit corneal epithelial cell line. j Pharm. Sci. (2001) 90:1505–1515.
  • GONZALEZ DE, COVITZ KM, SADEE W, MRSNY RJ: An oligopeptide transporter is expressed at high levels in the pancreatic carcinoma cell lines AsPc-1 and Capan-2. Cancer Res. (1998) 58:519–525.
  • •A description of cancer cell lines with high expression of peptide transporters.
  • NAKANISHI T, TAMAI I, TAKAKI A, TSUJI A: Cancer cell-targeted drug delivery utilizing oligopeptide transport activity. Int. Cancer (2000) 88:274–280.
  • BOYD CA, WARD MR: A micro-electrode study of oligopeptide absorption by the small intestinal epithelium of Necturus maculosus.J. Physiol Lond. (1982) 324:411–428.
  • FERRARIS RP, DIAMOND J, KWAN WW: Dietary regulation of intestinal transport of the dipeptide carnosine. Am. Physiol (1988) 255:G143–G150.
  • RAJENDRAN VM, BERTELOOT A, ISHIKAWA Y, KHAN AH, RAMASWAMY K: Transport of carnosine by mouse intestinal brush-border membrane vesicles. Biochim. Biophys. Acta (1984) 778:443–448.
  • SUPURAN CT, BRIGANTI F, TILLI S, CHEGWIDDEN WR, SCOZZAFAVA A: Carbonic anhydrase inhibitors: sulfonamides as antitumor agents? Bioorg. Med. Chem. (2001) 9:703–714.
  • SUPURAN CT, SCOZZAFAVA A: Carbonic anhydrase inhibitors: aromatic sulfonamides and disulfonamides act as efficient tumor growth inhibitors. .1 Enzyme Inhib. (2000) 15:597–610.
  • MASTROLORENZO A, SCOZZAFAVA A, SUPURAN CT: 4- Toluenesulfonylureido derivatives of amines, amino acid and dipeptides: a novel class of potential antitumor agents. Ear. Phann. Sci. (2000) 11:325–332.
  • NIELSEN CU, SUPURAN CT, SCOZZAFAVA A, FROKJAER S, STEFFANSEN B, BRODIN B: Transport characteristics of L-carnosine and the anticancer derivative 4-toluenesulfonylureido-carnosine in a human epithelial cell line. Pliant]. Res. (2002) (In Press).
  • KUPCZYK-SUBOTKOWSKA L, TAMURA K, PAL D et al.: Derivatives of melphalan designed to enhance drug accumulation in cancer cells. j. Drug Target. (1997) 4:359–370.
  • LEE VH, SPORTY JL, FANDY TE: Pharmacogenomics of drug transporters: the next drug delivery challenge. Adv. Drug Deify. Rey (2001) 50\(Suppl. 1):S33–S40.
  • SAITO H, TERADA T, OKUDA M, SASAKI S, INUI K: Molecular cloning and tissue distribution of rat peptide transporter PEPT2. Biochlin. Biophys. Acta (1996) 1280:173–177.
  • EDDY EP, WOOD C, MILLER J, WILSON G, HIDALGO IJ: A comparison of the affinities of dipeptides and antibiotics for the di-hripeptide transporter in Caco-2 cells. Int. J. Pitapat. (1995) 115:79–86.
  • HAN HK, RHIE JK, OH DM et al: CHO/hPEPT1 cells overexpressing the human peptide transporter (hPEPT1) as an alternative in vitromodel for peptidomimetic drugs. I Phann. Sci. (1999) 88:347–350.
  • TAKAHASHI K, NAKAMURA N, TERADA T et al.: Interaction of P-lactam antibiotics with HE/peptide cotransporters in rat renal brush-border membranes. Phannacol. Exp. The]: (1998) 286:1037–1042.
  • GANAPATHY ME, PRASAD PD, MACKENZIE B, GANAPATHY V, LEIBACH FH: Interaction of anionic cephalosporins with the intestinal and renal peptide transporters PEPT 1 and PEPT 2. Broclutn. Biophys. Acta (1997) 1324:296–308.
  • MATSUMOTO S, SAITO H, INUI K: Transport characteristics of ceftibuten, a new cephaloporin antibiotic, via the apical H+/dipeptide cotransport system in human intestinal cell line Caco-2: regulation by cell growth. Phann. Res. (1995) 12:1483–1487.
  • KRAMER W, GIRBIG F, GUTJAHR U, KOWALEWSKI S, ADAM F, SCHIEBLER W: Intestinal absorption ofl3-lactam antibiotics and oligopeptides. Functional and stereospecific reconstitution of the oligopeptide transport system from rabbit small intestine. Eur:j. Bloc:hem (1992) 204:923–930.
  • DANTZIG AH, BERGIN L: Uptake of the cephalosporin, cephalexin, by a dipeptide transport carrier in the human intestinal cell line, caco-2. Biochlin. Biophys. Acta (1990) 1027:211-217. BRANDSCH M, BRANDSCH C, GANAPATHY ME, CHEW CS, GANAPATHY V, LEIBACH FH: Influence of proton and essential histidyl residues on the transport kinetics of the HE/peptide cotransport systems in intestine (PEPT 1) and kidney (PEPT 2). Biochlin .Biophys. Acta (1997) 1324:251–262.
  • DANTZIG AH, DUCKWORTH DC, TABAS LB: Transport mechanisms responsible for the absorption of loracarbef, cefixime, and cefuroxime axetil into human intestinal Caco-2 cells. Biochlin. Biophys. Acta (1994) 1191:7–13.
  • TEMPLE CS, BOYD CA: Proton-coupled oligopeptide transport by rat renal cortical brush border membrane vesicles: a functional analysis using ACE inhibitors to determine the isoform of the transporter. Biochim. Biophys. Acta (1998) 1373:277–281.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.